Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis
详细信息 查看全文
- 作者：Xiaojun Qi ; Haibo Shao ; Jian Zhang ; Ziping Sun ; Yicheng Ni ; Ke Xu
- 关键词：Hypericin ; Necrosis ; Radiofrequency ablation ; Radiopharmaceutics
- 刊名：La radiologia medica
- 出版年：2015
- 出版时间：February 2015
- 年：2015
- 卷：120
- 期：2
- 页码：213-221
- 全文大小：743 KB
- 参考文献：1. Friedman M, Mikityansky I, Kam A et al (2004) Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol 27:427-34
2. Ni Y, Mulier S, Miao Y et al (2005) A review of the general aspects of radiofrequency ablation. Abdom Imaging 30:381-00 CrossRef
3. Guan YS, Sun L, Zhou XP et al (2004) Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. World J Gastroenterol 10:3543-548
4. King AD, Tse GM, Ahuja AT et al (2004) Necrosis in metastatic neck nodes: diagnostic accuracy of CT, MR imaging, and US. Radiology 230:720-26 CrossRef
5. Goldberg SN (2005) Science to practice: can we differentiate residual untreated tumor from tissue responses to heat following thermal tumor ablation? Radiology 234:317-18 CrossRef
6. Van de Putte M, Wang H, Chen F et al (2008) Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep 19:927-32
7. Van de Putte M, Wang H, Chen F et al (2008) Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol 15:107-13 CrossRef
8. Fonge H, Van de Putte M, Huyghe D et al (2007) Evaluation of tumor affinity of mono-[(123I]iodohypericin and mono-[(123I]iodoprotohypericin in a mouse model with a RIF-1 tumor. Contrast Media Mol Imaging 2:113-19 CrossRef
9. Ni Y, Huyghe D, Verbeke K et al (2006) First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 33:595-01 CrossRef
10. Van de Putte M, Marysael T, Fonge H et al (2012) Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int J Cancer 131:E129–E137 CrossRef
11. Cona MM, Koole M, Feng Y et al (2014) Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic. Int J Oncol 44:819-29
12. Song S, Xiong C, Zhou M et al (2011) Small-animal PET of tumor damage induced by photothermal ablation with 64Cu-bis-DOTA-hypericin. J Nucl Med 52:792-99 CrossRef
13. Li J, Cona MM, Chen F et al (2013) Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. Theranostics 3:127-37 CrossRef
14. Li J, Sun Z, Zhang J et al (2011) A dual-targeting anticancer approach: soil and seed principle. Radiology 260:799-07 CrossRef
15. Dalmo J, Rudqvist N, Spetz J et al (2012) Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2. Oncol Rep 27:174-81
16. Ali SM, Olivo M (2002) Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells. Int J Oncol 21:531-40
17. Ji Y, Zhan Y, Jiang C (2014) Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. J Drug Target 22:304-12 CrossRef
18. Schwarz RE, Smith DD (2008) Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg 195:829-36 CrossRef
19. Cona MM, Feng Y, Li Y et al (2013) Comparative study of iodine-123-labeled hypericin and 99mTc-labeled hexakis [2-methoxy isobutyl isonitrile] in a rabbit model of myocardial infarction. J Cardiovasc Pharmacol 62:304-11- 刊物主题：Imaging / Radiology; Diagnostic Radiology; Interventional Radiology; Neuroradiology; Ultrasound;
- 出版者：Springer Milan
- ISSN：1826-6983
文摘
Purpose Hypericin (HYP) has been found avid to necrosis in small animal studies. We sought to evaluate the tissue distribution of 131I-HYP in a large animal model and to explore the theranostic utilities of 131I-HYP after radiofrequency ablation (RFA). Materials and methods This animal experiment was approved by the institutional ethics committee. Twenty-five male dogs were enrolled and subjected to transabdominal hepatic RFA. 131I-HYP was prepared by an electrophilic substitution method and intravenously administered at 0.5?mCi/kg. Systemic and regional distributions of 131I-HYP were monitored dynamically by single-photon emission computed tomography/computed tomography (SPECT-CT), gamma counting, autoradiography, and fluorescent and light microscopy at different time points up to 14?days. Experimental data were quantified and statistically analysed. Results Most of the tissues and organs retained 131I-HYP only transiently. 131I-HYP was mainly metabolised in the liver and excreted into the bile. 131I-HYP gradually accumulated in the RFA-induced necrosis with a peak concentration occurring within 2?days and lasting over 2?weeks as visualised by in vivo SPECT-CT and ex vivo autoradiography and fluorescent microscopy, and quantified by radioactivity and fluorescence measurements. Accumulation of 131I-HYP was low in both the necrosis centre and normal liver tissue. Conclusion 131I-HYP showed persistent high affinity to hepatic thermo-coagulative necrosis, but only a transient uptake by normal liver in dogs. Necrosis caused by RFA could be indicated by 131I-HYP on nuclear imaging, which suggests a supplementary measure for tumour detection and therapy.